$268.22 0.00 (0.00%)

ResMed Inc. (RMD)

ResMed Inc. is a healthcare company that specializes in developing, manufacturing, and marketing medical equipment primarily for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Founded in 1989, the company is known for its innovative sleep and respiratory care solutions, including devices such as CPAP machines, ventilators, and related accessories. ResMed operates globally, serving both individual patients and healthcare providers.

Dividend Yield 0.82%
Payout Frequency Quarterly

Dividend History

Pay DateAmountEx-DateRecord Date
September 18, 2025$0.602025-08-142025-08-14
June 12, 2025$0.532025-05-082025-05-08
March 20, 2025$0.532025-02-132025-02-13
December 12, 2024$0.532024-11-072024-11-07
September 19, 2024$0.532024-08-152024-08-15

Dividends Summary

Company News

Saudi Arabia $5.94 Bn Sleep Apnea Devices Market Trends, Competition, Forecast & Opportunities, 2030F Featuring ResMed, Philips, Invacare, Itamar Medical, and Nihon Kohden
GlobeNewswire Inc. • Research And Markets • October 7, 2025

The Saudi Arabia Sleep Apnea Devices Market is projected to grow from $4.35 billion in 2024 to $5.94 billion by 2030, driven by increasing awareness of sleep disorders and demand for diagnostic and therapeutic technologies.

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
Benzinga • Vandana Singh • April 24, 2025

ResMed reported strong Q3 results with double-digit EPS growth and a tariff exemption, leading analysts to boost their price forecasts for the company.

ResMed: Digital Health Drives Q2 Growth
The Motley Fool • Jesterai • January 31, 2025

ResMed, a leader in sleep apnea and respiratory care solutions, reported robust fiscal 2025 second-quarter earnings, surpassing analyst expectations. The strong performance was driven by high demand for sleep-related products and growth in digital health solutions.

Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics
Zacks Investment Research • N/A • August 1, 2024

ResMed reported revenue of $1.22 billion and EPS of $2.08 for Q2 2024, beating analyst estimates. The company saw growth across its various business segments, including devices, masks, and software as a service.

Here's a new way to consider value for stocks in the S&P 500
MarketWatch • MarketWatch • January 27, 2024

A look back at quality highlights companies that have made a lot of money for investors and are expected to grow earnings rapidly through 2025.

Related Companies